Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 19:49:49 GMT 2025
by
admin
on
Wed Apr 02 19:49:49 GMT 2025
|
| Protein Type | PEPTIDE |
| Protein Sub Type | T-CELL ANTIGEN |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
V62WR73538
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
255707-29-0
Created by
admin on Wed Apr 02 19:49:49 GMT 2025 , Edited by admin on Wed Apr 02 19:49:49 GMT 2025
|
PRIMARY | |||
|
V62WR73538
Created by
admin on Wed Apr 02 19:49:49 GMT 2025 , Edited by admin on Wed Apr 02 19:49:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->VACCINE ANTIGEN |
Cancer vaccine regimen combining human telomerase reverse transcriptase (hTERT) peptides with concomitant therapies targeting regulatory T cells (Tregs) and cyclooxygenase-2 (COX2)-mediated immunosuppression.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
primary objective was determination of the safety and tolerability of this combination therapy, with anti-cancer activity, immune response and detection of antigen-specific T cells as additional endpoints.
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|